Health ❯ Healthcare ❯ Pharmaceuticals

Biosimilars

Cancer Treatment Regulatory Approvals Drug Approval FDA Approval Keytruda Nufymco Regulatory Guidance Insulin Synthetic Drugs Starjemza Teva Pharmaceuticals Gotenfia Ustekinumab User Fees Pertuzumab-dpzb Tyruko Enzeevu™ Bosaya™ and Vezuo™ Market Authorization FDA Guidance Regulatory Changes Clinical Data Teva Pharmaceutical Industries Insulin Glargine Regulatory History Rheumatoid Arthritis Treatments Safety Profile Ranibizumab Product Portfolio Stelara Semaglutide Drug Pricing Immuno-Oncology Insulin Products Yesintek Regulations Ophthalmology Oral Semaglutide FDA Approval Process Respiratory Drugs Biosimilar Drugs Market Opportunities

FDA Clears First Biosimilars to Simponi and Simponi Aria: IMMGOLIS and IMMGOLIS INTRI

The move opens biosimilar competition to Johnson & Johnson’s golimumab brands in arthritis and colitis care.

FDA Approves Langlara as Interchangeable Biosimilar to Lantus

FDA Clears Teva’s Ponlimsi, a Prolia Biosimilar, for All Indications

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer